- Home
- TSHA vs TXG Comparison
TSHA vs TXG Comparison
Compare TSHA & TXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- TXG
- Stock Information
- Founded
- TSHA 2019
- TXG 2012
- Country
- TSHA United States
- TXG United States
- Employees
- TSHA N/A
- TXG N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- TXG Biotechnology: Laboratory Analytical Instruments
- Sector
- TSHA Health Care
- TXG Industrials
- Exchange
- TSHA Nasdaq
- TXG Nasdaq
- Market Cap
- TSHA 1.3B
- TXG 1.6B
- IPO Year
- TSHA 2020
- TXG 2019
- Fundamental
- Price
- TSHA $5.13
- TXG $11.60
- Analyst Decision
- TSHA Strong Buy
- TXG Buy
- Analyst Count
- TSHA 8
- TXG 12
- Target Price
- TSHA $9.38
- TXG $13.54
- AVG Volume (30 Days)
- TSHA 11.6M
- TXG 2.6M
- Earning Date
- TSHA 11-12-2025
- TXG 11-06-2025
- Dividend Yield
- TSHA N/A
- TXG N/A
- EPS Growth
- TSHA N/A
- TXG N/A
- EPS
- TSHA N/A
- TXG N/A
- Revenue
- TSHA $8,098,000.00
- TXG $644,466,000.00
- Revenue This Year
- TSHA N/A
- TXG $2.11
- Revenue Next Year
- TSHA N/A
- TXG N/A
- P/E Ratio
- TSHA N/A
- TXG N/A
- Revenue Growth
- TSHA N/A
- TXG 2.02
- 52 Week Low
- TSHA $1.05
- TXG $6.78
- 52 Week High
- TSHA $5.40
- TXG $18.21
- Technical
- Relative Strength Index (RSI)
- TSHA 72.82
- TXG 43.53
- Support Level
- TSHA $4.70
- TXG $11.18
- Resistance Level
- TSHA $5.21
- TXG $12.14
- Average True Range (ATR)
- TSHA 0.37
- TXG 0.59
- MACD
- TSHA 0.13
- TXG -0.03
- Stochastic Oscillator
- TSHA 88.35
- TXG 28.29
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About TXG 10x Genomics Inc.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).